How is the liquid intravenous immunoglobulin (IVIG) product KIOVIG prepared?

Updated: Jul 05, 2018
  • Author: Jessica Katz, MD, PhD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Baxter AG [28] created a new liquid intravenous immunoglobulin product (Immune Globulin Intravenous [IGIV] 10%) using a new manufacturing procedure. Baxter AG used a modified Cohn fractionation and ion exchange chromatography to produce an IgG solution with no alterations to the Fc region.

KIOVIG™ (Immune Globulin Intravenous [Human]) is one name for this product. KIOVIG has obtained marketing authorization from the European Medicines Agency (EMEA). KIOVIG is indicated in the European Union for replacement therapy in primary immunodeficiency disorders (PID), myeloma or chronic lymphocytic leukemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections, children with congenital AIDS and recurrent infections, Kawasaki syndrome, allogeneic bone marrow transplantation, Guillain-Barré Syndrome, and idiopathic thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgery to correct the platelet count. [29]

The significance of IgA content in these preparations for patients with IgA deficiency is unclear.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!